PubMed · 2010 · 61 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyCancer Cell SignalingOncogenic Signaling PathwaysSignal Transduction In CancerTargeted Cancer TherapyTargeted TherapyEarly-phase Clinical TrialsPhosphoinositide 3-Kinase SignalingPi3 Kinase-akt SignalingPi3k InhibitorsPi3k SignalingPi3k-akt Signaling PathwaySuitable TargetTranslational Oncology Drug Development
PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.